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The b-hemoglobinopathies sickle cell anemia and b-thalassemia are the focus of many gene-therapy studies.
A key disease parameter is the abundance of globin chains because it indicates the level of anemia, likely toxicity
of excess or aberrant globins, and therapeutic potential of induced or exogenous b-like globins. Reversed-phase
high-performance liquid chromatography (HPLC) allows versatile and inexpensive globin quantification, but
commonly applied protocols suffer from long run times, high sample requirements, or inability to separate
murine fromhumanb-globin chains.The latterpoint is problematic for invivo studieswithgene-additionvectors
inmurine diseasemodels andmouse/human chimeras. This study demonstratesHPLC-basedmeasurements of
globinexpression (1)afterdifferentiationof thecommonlyappliedhumanumbilical cordblood–derivederythroid
progenitor-2 cell line, (2) in erythroid progeny of CD34+ cells for the analysis of clustered regularly interspaced
short palindromic repeats/Cas9-mediated disruption of the globin regulator BCL11A, and (3) of transgenicmice
holding the human b-globin locus. At run times of 8min for separation of murine and human b-globin chains as
well as of human c-globin chains, andwith routinemeasurement of globin-chain ratios for 12 nL of blood (tested
fordownto0.75nL)orof300,000 invitrodifferentiatedcells, themethodspresentedhereandanyvariant-specific
adaptations thereof will greatly facilitate evaluation of novel therapy applications for b-hemoglobinopathies.
Keywords: high-performance liquid chromatography, CRISPR/Cas9, gene addition, fetal hemoglobin,
b-hemoglobinopathy, thalassemia
INTRODUCTION
THE MAJOR HEMOGLOBINOPATHIES sickle cell anemia
(SCA) and thalassemia as a group represent the
commonestmonogenicdisorders.Themostsevereand
potentially lethal forms affect the components of the
main adult hemoglobin a2b2 tetramer (HbA). Where-
as SCA is caused by a pathologic b-globin HBBE6V
variant,1 a- and b-thalassemia are caused by loss or
depletion of the eponymous globin chain and conse-
quential toxic excess of its counterpart.2,3 Lifelong
managementwithblood transfusionsandmedication,
such as iron chelation to avoid iron overload and hy-
droxyl urea to reduce transfusion requirements in
SCA patients, reduces suffering by anemia, hemoly-
sis, and disease-related severe pleiotropic effects.
Such palliative treatment is prohibitively expensive
forstandardcare in low-andmiddle-incomecountries,
andposes thepersistent threatofbloodcontamination
and long-term damage to vital organs.4–10 Curative
treatment by allogeneic transplantation of hemato-
poietic stem cells, however, is only available to the
fraction of patients for whom suitable donors can be
identified and, despite ongoing improvements, carries
a significant risk of treatment-related mortality.11
The severity of hemoglobinopathies in combi-
nation with a high global disease burden, estimated
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annually at >330,000 affected births (17:3 SCA:
thalassemias),12 has prompted many laboratories
and companies to work toward therapies and cures.
For b-hemoglobinopathies in particular, these have
long included small-molecule drugs, but lately and
more successfully also include gene therapy treat-
ment of hematopoietic stem and progenitor cells
(HSPCs) either by gene addition, up to the level of
clinical trials, or by diverse approaches based on
genome editing.13,14 The latter field has seen tre-
mendous growth and scientific progress, especially
based on double-strand breaks introduced by de-
signer clustered regularly interspaced short palin-
dromic repeats (CRISPR)-guided endonucleases
and more recently based on CRISPR-directed base
editing.15 In the case of designer nucleases, target
genomic DNA sequences can be disrupted by im-
precise repair based on non-homologous end joining
(NHEJ), or can be modified in a targeted fashion in
the presence of suitable repair templates based on
homology-directed repair.
The cornerstone of drug-based and many gene
therapy strategies is that endogenous c-globin,
which is encoded by theHBG1 (Ac-globin) andHBG2
(Gc-globin) genes on the b-globin locus, may be
induced as a therapeutic substitute for b-globin by
transcriptional reprogramming of HSPCs. More-
over, c-globin and specific exogenous b-globin de-
signer variants have anti-sickling properties and
thus improved efficacy in the treatment of SCA
compared to wild-type b-globin. Gene addition vec-
tors for the treatment of b-hemoglobinopathies thus
provide exogenous b-globin or, for higher efficacy
in SCA, c-globin or anti-sickling b-globin vari-
ants.16 These and other gene addition approaches,
such as the activation of c-globin by provision of ar-
tificial transcription factors17 or by shRNA-mediated
knockdown of c-globin repressors,18 conceptually
depend on permanent and usually lentiviral deliv-
ery of the therapeutic transgene. For clinical appli-
cation of therapies based on genome editing,
delivery of designer nucleases or base editors, and
possibly of specific repair templates, will instead be
transient. Therapeutic strategies currently under
investigation are the recreation of deletions associ-
atedwith high c-globin levels in the b-globin locus,19
the deletion of specific control elements required for
maintenance of low c-globin levels,20 or the repair of
the specific causative mutation and thus reinstate-
ment of normal b-globin expression.15,21–23 What-
ever additional approaches may be explored in this
fast-moving field, quantitative assessment of thera-
peutic efficiency is and will remain critical.
A key parameter for the assessment of thera-
peutic efficiency is the ratio of b-like to a-like globin
chains, which in normal adults is 1:1. This should
give a ratio slightly <1 for b- to a-globin, owing to
their stoichiometric 1:1 contribution to HbA (>95%
of total hemoglobin) and the additional presence of
normally minor quantities of a2d2 (HbA2, <3.5%)
and a2c2 (residual fetal hemoglobin, HbF, <1%)
heterotetramers in adult blood. To this end, im-
munoblots are a frequently applied research
method for protein quantification, but are charac-
terized by high sample requirements, high reagent
cost, and low reproducibility of measurements
across experiments because of the requirement of
multiple blots for internal controls and calibra-
tors.24 Moreover, the relative purity of globin
chains in blood and erythroid samples renders
antibody recognition unnecessary for the specific
purpose of globin-chain detection, as hemoglobin
makes up 99% of erythroid dry mass.25 This
knowledge is exploited by routine diagnostic
methods widely applied for population screening
of hemoglobinopathies, such as cation-exchange
high-performance liquid chromatography (HPLC),26
isoelectric focusing,27 or cellulose acetate electro-
phoresis,28 which rely on the detection of hemo-
globin tetramers and, particularly if applied in
combination,29 allow sensitive detection of differ-
ent hemoglobin variants. However, those methods
give limited information on the specific quantities
of constituting chains, in particular for the c-globin
chains, Ac and Gc, which differ by a single amino
acid. In partially differentiated cell culture sam-
ples or chimeric models, these limitations are ex-
acerbated by the presence of additional proteins or
hybrid hemoglobin species. Advanced proteomics
approaches achieve high levels of specificity and
sensitivity,30 but their application is limited to few
specialized laboratories. Widely accessible, robust
detection of individual globin chains may instead
be achieved by reversed-phase HPLC (RP-HPLC),
which separates proteins based on their hydro-
phobicity.31
RP-HPLC data are commonly used in cell and
gene therapy publications, but frequently source
data are not shown at all32–34 or indicate technical
shortcomings (such as sloping baselines).35 Proto-
col optimization for RP-HPLC based on C4 column
resin has resulted in sensitive detection of down to
0.1lg hemoglobin36 and baseline separation of all
human globin species,37 but at runtimes of 70min
and 100min, respectively, that are too long for
routine application. The most significant speed
improvement in RP-HPLC application to hemo-
globinopathies has come about by a change of col-
umn materials (C18 instead of C4 resin) in two
studies, but without data for cell culture or animal
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samples.38,39 Moreover, both advanced protocols
employed high-pressure gradient systems at
speeds of 3.5mL/min38 or 2.0mL/min,39 at which
the low-pressure gradient systems commonly used
in research settings cannot achieve satisfactory
mixing of the mobile phases used. In both cases,
change of column material reduced peak widths
and thus reduced run times down to 16min, but
both reports utilized liberal (0.48lL of blood)39 to
apparently excessive (hemoglobin equivalent to
1mL of blood)38 sample material per injection. In
the former study, this would already be equivalent
to >2· 106 erythrocytes per single readout. Exist-
ing sensitive research protocols therefore suffer
from long run times, whereas diagnostic protocols
are not optimized for minimal sample utilization.
Accordingly, the overall framework parameters of
existing RP-HPLC protocols are not suitable for
gene therapy work, where sample material is al-
ways limited, numerous samples call for short run
times, c-globin chains are routinely of great in-
terest, and close to clinical application, measure-
ment of human globin chains in the background of
transgenic or chimeric murine models is required.
This study therefore sought to accommodate short
run times, measurement at far-UV wavelengths,
common low-pressure gradient technology, and
measurement of murine and human globin chains
usually encountered in gene-therapy work in a
clearly defined set of RP-HPLC parameters for the
authors’ own experimentation and as a common
reference in the field.
MATERIALS AND METHODS
Study subjects and human blood collection
All experimentation on human peripheral blood
(PB) and PB-derived cells was based on approval by
the Cyprus National Bioethics Committee (Appli-
cations EEBK/EII/2012/02 ‘‘Advancing Gene
Therapy Vectors for Thalassaemia’’ and EEBK/EII/
2013/23 ‘‘ThalaMoSS’’) and on written informed
consent by all study subjects. Human blood sam-
ples were collected in VACUETTE tubes with
EDTA-anticoagulation (Greiner Bio-One). Avail-
able to this study was donor blood from healthy
adult and cord blood controls, from both a carrier
and a homozygous patient for the HBBIVSI-110(G>A)
mutation, and from a homozygous HBBE6V (SCA)
patient. For characterization of the standard sep-
aration protocol (Table 1), combination of adult
(primarily HbA, a2b2) and cord blood (primarily
HbF, with greatest contribution a2
Gc2 and second-
arily a2
Ac2) analyses served to determine elution
times of human a-, b-, Gc-, and Ac-globin chains.
Purified HbA2 (H0266; Sigma–Aldrich) served as a
standard for d-globin elution times.
Mice and murine blood collection
Transgenic mice carrying the human b-globin
locus were gratefully received from Dr. Kenneth R.
Peterson (University of Kansas, Lawrence, KS).
Other mice were commercial strains obtained from
Harlan/Envigo. Murine blood was collected with
EDTA as anticoagulation agent (1.5lL of 0.5M
EDTA, pH 8.0 for up to 250lL of blood) and stored
at 4C until processing. All handling of animals
followed institutional guidelines and regulations.
Unless indicated otherwise, mouse samples em-
ployed in this study were based on C57BL/6J
(C57Bl/6J/OlaHsd) genetic background and the
corresponding Hbbs haplotype, resulting in a typi-
cal single murine b-globin peak.40 Analysis of pe-
ripheral blood samples for C57BL/6Jmice andYAC
mice, which show reduced murine Hbbs expression
owing to competition with the human b-globin lo-
cus, were used to identify elution times for C57BL/
6J a- and b-globin chains (Supplementary Fig. S1).
Other mouse lines used to characterize the hybrid
(murine/human) separation protocol (Table 2) were
Table 1. RP-HPLC protocol for human globin chains
Time (min) Phase B (%) Comment
1 43 +3%/min during injection
5 50 +1.75%/min; main elution gradient
6 40 Return to baseline mobile phase
8 40 Stop
Besides the parameters defined here, precise elution times and peak
separation will also depend on variation in tube lengths and diameters,
column packing, and the degree of deterioration of guard and main column.
Baseline mobile phase 40% B; column temperature 70C; flow speed
1.0 mL/min; max. backpressure (at injection) 90 bar (9MPa, 1,305 psi).
RP-HPLC, reversed-phase high-performance liquid chromatography.
Table 2. Hybrid RP-HPLC protocol
Time (min) Phase B (%) Comment
1 36.5 Baseline mobile phase for 1 min
2 40 +3.5%/min; elution of Mm a
6 48 +2%/min; main elution gradient
7 36.5 Return to baseline mobile phase
8 36.5 Stop
The RP-HPLC protocol optimized for low run times and good separation of
murine and human b-globin chains at good peak widths. Alternative
conditions exist that will give either superior separation or narrower peak
shape for the same stationary and mobile phases (see Supplementary
Fig. S2).
Besides the parameters defined here, precise elution times and peak
separation will also depend on variation in tube lengths and diameters,
column packing, and the degree of deterioration of guard and main column.
Baselinemobile phase 36.5%B; column temperature 0–4C (on ice); flow speed
1.0mL/min; max. backpressure (at injection) 360 bar (36MPa, 5,220 psi). Applying a
lower flowspeed of 0.8mL/minwill reduce backpressure to amaximumof 320 bar,
at slight delay and broadening of elution peaks (data not shown).
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Balb/c (Balb/cOlaHsd), CBA (CBA/CaOlaHsd),
DBA (DBA/2OlaHsd), andCD-1 (Hsd:ICR(CD-1)).
Lentiviral vector production
Lentiviral (LV) vectors were produced as re-
ported.41 Briefly, near-confluent HEK293T cells
were seeded 1:8 in 100mm TC-treated culture
dishes (Sigma–Aldrich) and 8mL complete Dul-
becco’s modified Eagle’s medium (cDMEM: DMEM,
10% fetal bovine serum [FBS], 1· penicillin/
streptomycin, and 1% GlutaMAX; Thermo Fisher
Scientific). Next day, 100lg of polyethylenimine
(PEI; Polysciences, Inc.) in 500lL 1 ·HBS
(140.5mM of NaCl, 50mM of HEPES, 0.75mM of
Na2HPO4, pH 7.1–7.14) per dish were mixed with
5 lg of envelope plasmid pMD2_VSVG, 15lg of
packaging plasmid psPAX2, and 20 lg of transfer
vector (lentiCRISPRv242 constructs expressing
start codon-specific [5¢-GCTTGCGGCGAGACATG
G-3¢] and exon1-specific [5¢-GCTGGGGTTTGCCT
TGCTTG-3¢] sgRNAs and Cas9 endonuclease), in-
cubated for 20min at room temperature and added
to HEK293T cultures in fresh 6mL of DMEM,
supplemented with 1% FBS and 1· penicillin/
streptomycin. Medium was replaced with 8mL of
cDMEM at 4h after transduction and after collec-
tion of vector-containing supernatant at 24 and
48h, with a final collection at 72h. Supernatant was
kept at 4C throughout, filtered (0.45lm poly-
vinylidene fluoride; Merck Millipore), and centri-
fuged at 20,000 g for 4h at 4C. The resulting vector
pellet was suspended in 100lL of StemSpan SFEM
II (STEMCELL Technologies) medium (240· con-
centration) and stored at -80C. For the purpose of
this study, vector-containing supernatants were
used for transduction without vector titration or
subsequent assessment of vector copy number.
Expansion and differentiation of human
umbilical cord blood–derived erythroid
progenitor-2 cells
Human umbilical cord blood–derived erythroid
progenitor-2 (HUDEP-2) cells43 were maintained
in SFEM II, supplemented with 100ng/mL of hu-
man stem cell factor (hSCF; PeproTech), 10–6 M
dexamethasone (Sigma–Aldrich), 5lg/mL of doxy-
cycline (Clontech Laboratories), 3 IU/mL erythro-
poietin (EPO; Binocrit 4,000; Sandoz GmbH), and
2·penicillin/streptomycin (Thermo Fisher Scien-
tific). Cells were cultured at a density of 0.5–1·106/
mL in 25cm2Nunc flasks (ThermoFisher Scientific)
and incubated at 37C in 5% CO2 humidified at-
mosphere. Of note, SFEM II was used as basal
medium instead of Iscove’s Modified Dulbecco’s
Medium (IMDM) suggested by the original proto-
col.43 Comparison of both identically supplemented
media resulted in 24% higher cell death inHUDEP-
2 samples cultured with IMDM instead of SFEM II
at day 4 of differentiation (data not shown).
Erythroid differentiation was induced by trans-
fer of cells into StemSpan SFEM II containing 2%
FBS (qualified, Australian origin; Thermo Fisher
Scientific), 3% human serum (Sigma–Aldrich), 3%
human plasma (harvested as supernatant of double-
centrifuged EDTA-anticoagulated donor blood),
3 IU/mL EPO, 10lg/mL of insulin, 1,000lg/mL of
holo-transferrin, 3 IU/mL heparin (all from Sigma–
Aldrich), 2·penicillin/streptomycin at a cell density
of 1·106/mL, and 2.5lg/mL of doxycycline. Two
days after the induction of differentiation, the dif-
ferentiation medium was topped up to maintain
cellular density, and doxycycline-containing cultures
were additionally supplemented with 1.25lg doxy-
cycline per mL of old medium. Differentiated
HUDEP-2 cells were harvested for analyses at day 4
of differentiation.
Isolation, expansion, transduction, and
differentiation of human CD34+ (hCD34+) cells
PB-derived human CD34+ (hCD34+) cells were
isolated according to Protocol C, established
by Cosenza et al.44 Expanded cells at day 6 post-
isolation were cultivated in 10mL of expansion
medium at a density of 0.5· 106/mL, composed of
10mL of StemSpan SFEM II, 100lL of StemSpan
CC100 Cytokine Cocktail (STEMCELL Technolo-
gies), 10–6 M of dexamethasone, 1·penicillin/
streptomycin, and 2 IU/mL of EPO to promote
survival and efficient expansion of erythroid cells.
Cellular expansion was continued until day 10,
resulting in a total number of 21.6 ·106 cells.
CD34+ cells (1.1–1.5 ·106) were seeded in each
well of a 12-well plate (Iwaki, Asahi Glass Co.),
filled up to 2mLwith expansionmedium. After 1h,
50–75 lL of concentrated LV vector (first trans-
duction step) was added to each well, and the plate
was rocked back and forth several times. Twenty-
four hours later, cells were gently re-suspended,
ensuring homogeneous cellular distribution, and
1h later, an additional 50–75 lL of LV vector was
added in each culture (second transduction step).
After an additional 24h, 500lL of fresh expansion
medium containing 5lg/mL of puromycin (Santa
Cruz Biotechnology) was added in each well, initi-
ating the enrichment of the virally transduced cells
at a final concentration of 1lg/mL of puromycin.
For transduction with our HBBT87Q version45 of
the GLOBE vector,46 a single-hit transduction was
performed instead, as described elsewhere,47 in-
cluding hourly agitation for 6 h after transduction.
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Differentiation of the untransduced controls and
transduced hCD34+ cells was induced 24h after
initiating puromycin selection by cultivating cells
in differentiation medium composed as follows:
70% a-Minimum Essential Medium (a-MEM;
Corning CellGro), 30% FBS defined (HyClone
Laboratories, Inc.), 10–5 M 2-mercaptoethanol
(Sigma–Aldrich), 10 IU/mL of EPO, 10ng/mL of
hSCF, and 1 ·penicillin/streptomycin. Cells were
differentiated at a concentration of 0.5–1 · 106/mL
for 4 days before their harvest for analyses. Fresh
differentiation medium (1.5mL) was added at day
2 of differentiation.
T7 endonuclease I assay
T7 endonuclease I (T7EI) assay was performed as
previously described,48 withminor changes, andwas
based on extracted genomic DNA of hCD34+ cells
48h post-transduction and 24h after puromycin-
mediated selection. T7E1 assays were thus applied
at a time point when DNA quality and yield were
high, but before the culture endpoint, when DNA
yield would be poor but when disruption effi-
ciencies from lentivirally encoded endonucleases
would still be higher. As extrapolated from inde-
pendent transductions with endonucleases, effi-
ciencies at the culture endpoint can be expected
to be approximately 3.6· the efficiency observed
here (unpublished data). In brief, a primer pair
(Exon1_FW 5¢-AAAGCCATGACGGCTCTCCCAC
AAT-3¢; Exon1_RV 5¢-CGGCAATGGTTCCAGAT
GGG-3¢), flanking the CRISPR/Cas9 target sites
(start codon and exon 1) was used to polymerase
chain reaction (PCR) amplify the target region of
edited and mock-treated cells, respectively, as tem-
plate. Subsequently, the purified PCR amplicons
were denatured and slowly annealed to create het-
eroduplexes with loop-out regions at editing events,
which were identified by digestion for 20min at
37C with 6 units of T7EI (New England Biolabs)
and by analysis of products by agarose (2.5%) gel
electrophoresis, before densitometric determination
of band intensities and calculation of disruption ef-
ficiencies. Fold changes that are shown in par-
entheses in themain text, but no other values in text
or figures, show values normalized for initial dif-
ferential disruption efficiencies of CRISPR/Cas9-
treated samples, so that those values give an ap-
proximate extrapolation of the c-globin level that
would be expected at 100% disruption efficiency. To
this end, the baseline Cas9-only c-globin level was
subtracted from that measured for CRISPR/Cas9
samples, dividing the result by the respective dis-
ruption efficiency and adding back to that quotient
the Cas9-only baseline c-globin level.
Sanger sequencing and TIDE analysis
Exon1_FW/Exon1_RV-amplified PCR products
spanning the CRISPR/Cas9 target sites were also
subjected to Sanger sequencing based on the Big-
Dye Terminator v3.1 Cycle sequencing kit (Applied
Biosystems) using Exon1_FW as sequencing pri-
mer and 25 cycles of 96C for 10 s, 50C for 5min,
and 60C for 4min on a Veriti thermocycler (Life
Technologies). After purification on Performa DTR
Gel Filtration Cartridges (Edge Biosystems), mixed
sequencing traces spanning the target site were
produced by capillary electrophoresis on a Hitachi
3031xl Genetic Analyzer with Sequence Detection
Software v5.2 (Life Technologies). Tracking of In-
dels by DEcomposition (TIDE; https://tide.nki.nl)
was then used to decompose the mixed traces and
determine the insertion and deletion pattern typical
of the designer nucleases in hand.49
Immunoblot assay
Cells were washed and re-suspended in 20 lL of
radioimmunoprecipitation lysis buffer (20mM of
Trizma-HCl [pH 7.4], 150mM of NaCl, 1% NP40,
0.1% sodium dodecyl sulfate, 0.5% sodium deox-
ycholate, 5mM of EDTA; all Sigma–Aldrich) per
1·106 cells, supplemented with 1·protease inhib-
itors (Roche), for analysis of total cellular protein.
After centrifugation, the supernatantwasmixed 1:1
with sample buffer (0.125Mof Trizma-HCl [pH6.8],
2% SDS, 21% glycerol, 4% b-mercaptoethanol,
0.05% bromophenol blue). Lysate equivalent to
0.5·105 and 2.5· 105 cells per well, for detection
of a-globin and c-globin, respectively, and corre-
sponding b-actin bands, were loaded in parallel
with a molecular weight protein marker (Nippon
Genetics) on sodium dodecyl sulfate/polyacryl-
amide gels, separated by electrophoresis and blot-
ted onto nitrocellulose Parablot NCP membranes
(Macherey-Nagel GmbH) using wet electropho-
retic transfer. Subsequently, quantitative protein
transfer was confirmed by staining of membranes
with Ponceau Red solution (Sigma–Aldrich), before
blocking and overnight incubation with primary
antibodies at 4C, specifically anti-c-globin (51-7)
mouse monoclonal IgG1 (#sc-21756), anti-a-globin
(H-80) rabbit polyclonal IgG (#sc-21005; both Santa
Cruz Biotechnology, Inc.; dilution at 1:1,000), and
anti-b-actin (AC-15) mouse monoclonal IgG1 (#A-
1978; Sigma–Aldrich; dilution 1:10,000). There-
after, washed membranes were incubated with the
corresponding horseradish peroxidase–conjugated
secondary antibody, specifically Goat-aMm-IgG
(H + L) (#115-035-003) or Goat-aRabbit-IgG(H+L)
(#111-035-003; both at 1:8,000; Jackson Immuno-
Research Laboratories). Bands were visualized
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using chemiluminescence detection (Lumisensor;
GenScript), captured using a UVP Biospectrum
810 Imaging system (UVP) with VisionWorks LS
7.1 software, and quantified using the ImageJ
quantification software. For the a-globin blot
shown, linear image adjustment in Photoshop
(Levels from 255 down to 109; Adobe) was required
to reduce excessive background signal and allow
band quantification.
Cytocentrifugation samples
For phenotypic characterization, differentiated
hCD34+-derived cells were cytocentrifuged on a
Cellspin II with an EASY rotor (Tharmac/Hettich)
and sequentially stained in dianisidine (1.5% o-
Dianisidine; Sigma–Aldrich; in methanol) for
2min, in H2O2/ethanol solution (50% ethanol, 0.9%
H2O2 in distilled water) for an additional 2min, in
May–Gru¨nwald staining solution (Sigma–Aldrich)
for 5min, and finally in Giemsa staining solution
(Fluka Analytica; Sigma–Aldrich) for 10min. After
a rinse in distilled water, sample slides were air-
dried and mounted (Entellan; Merck) with a cov-
erslip. Slides were visualized under an IX73P1F
inverted microscope, using LED illumination, a
40· lens, an XC50 camera, and averaging seven
frames per image in CellSens 1.7 (Olympus Corp.).
RP-HPLC analysis
In line with routine procedures for RP-HPLC
analysis of thalassemic samples,38,39,50 blood sam-
ples were lysed in HPLC-quality distilled water
(H2O; 4lL of PB in 996lL of H2O), vortexing and
incubating at room temperature for 10min. For cell
culture samples, the sample material was centri-
fuged at 2,000 RCF for 10min, re-suspended in
15lL of H2O/300,000 cells, and twice frozen at
-80C and thawed. After 10min of centrifugation
at 21,000 RCF and 4C, 800lL of PB lysate were
transferred into HPLC vials and 9/10 volume of
culture-derived lysate to 100-lL HPLC microvials
inside HPLC vials, respectively (all Altmann Ana-
lytik). This study did not analyze the resulting cell
pellet for residual protein content or globin aggre-
gates. Unless indicated otherwise, 3lL of blood
lysate (equivalent to 12 nL of blood) and 15lL of
HbA2 (Sigma–Aldrich; 200ng/lL) or culture-
derived lysate (equivalent to 300,000 cells), re-
spectively, were injected per HPLC run.
Analyses were performed on a modular Promi-
nence HPLC machine with an SPD-M20A diode
array detector, an LC-20AD (low-pressure gradi-
ent) binary pump, and an SIL-20AC HT cooled
autosampler to facilitate automated overnight
runs (all Shimadzu). The stationary phase was an
Aeris Widepore 3.6lm XB-C18 25 cm 4.6mm col-
umn behind a SecurityGuard UHPLC Widepore
C18 4.6mm guard column (all Phenomenex). Mo-
bile phases were Phase A: 0.1% trifluoroacetic acid
(TFA; Sigma–Aldrich) and 0.033% (6.4mM) so-
dium hydroxide (330 lL per liter of 19.4M NaOH;
50% NaOH for HPLC; Fluka), resulting in pH 3.0,
and Phase B: 0.1% TFA in acetonitrile (E-CHRO
MASOLV for HPLC; Sigma–Aldrich). Gradients
used were as given in Tables 1 and 2. Reagent cost,
excluding glassware and column depreciation, is
between e0.05 and e0.10 per sample, with aceto-
nitrile (at a current price of e30 per 2.5L through
government tenders in Cyprus) as the main re-
agent expense.
RESULTS
Separation of human globin chains
Toward lowered backpressure and greatest peak
capacity and thus possibly reduced separation
times, an HPLC column with core-shell technology
was chosen.51 The specific column, a Phenomenex
Aeris Widepore XP-C18, was selected as a replace-
ment of a previous fully porousC18 column,38,39 and
has certified stability at pH 1.5–9.0, at back-
pressures up to 600 bar (60MPa) and at tempera-
tures up to 90C. To minimize background noise in
the analysis of rare samples at far-UV absorbance
measurements, the study additionally drew on
acetonitrile supplemented with 0.1% TFA without
inclusion of other organic solvents as the organic
mobile phase. As aqueous phase, 0.1% TFA was
chosen, adjusted from pH 1.9 to 3.0 with 0.033%
(6.4mM) sodium hydroxide for increased column
life. Likewise, 70C was chosen as the highest
routine separation temperature to extend column
Figure 1. Reversed-phase high-performance liquid chromatography (RP-HPLC) separation of human control samples. Chromatograms of
human samples with readout at 190 nm (1 nm bandwidth) for injection of 12 nL peripheral blood (in panels PB, CB, and HbS) in a volume of 3lL, background-
subtracted for a 3lL water-only sample. Analyses are shown for peripheral blood (PB), cord blood (CB), purified HbA2 (an a2d2 heterotetramer), and HbS.
Injection is visible as a peak at 2.2 min. Other relevant peaks are identified underneath each chromatogram as b-globin (b), sickling b-globin (bS), d-globin (d),
Gc-globin (Gc), a-globin (a), Ac-globin (Ac), and heme (h). Differing absorbance ratios for the total of b-like globins compared to a-globin are in part caused by
differential molar absorption of different globin chains. Colored insets show contour plots for the PDA detector from 190 to 400 nm (on the vertical axis; tick
marks indicate 200 nm and 50-nm increments from top to bottom) and 0 to 8min (on the horizontal axis; tick marks indicate 0min and 2-min increments from left
to right). Heme can readily be discerned from other peaks by a local absorbance maximum close to 400 nm. Measurements and ratios for this figure are
summarized in Supplementary Table S1.
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life, although still higher temperatures within the
stability range gave even smaller peak widths and
baseline separation of relevant peaks (see Supple-
mentary Fig. S3; the effect is most pronounced for
heme), potentially allowing a further reduction of
runtimes for specific applications. After testing
many permutations of gradients, temperatures, and
speeds of the mobile phase (see Supplementary
Fig. S4 for exemplary separations at 70C column
temperature), the study adopted for sample injec-
tion during an initial 1min gradient for human
samples, as it was found that this gave the nar-
rowest peak widths for human a- and b-like globins.
The protocol arrived at for rapid baseline separa-
tion of all human globins found in normal adults
is shown in Table 1 and compares favorably in
every aspect with separations on columns previ-
ously used in the authors’ laboratory (see Supple-
mentary Fig. S5). The sensitivity of the protocol is
demonstrated in Fig. 1 for separations of the
equivalent of 12 nL commonly encountered human-
derived blood samples and the peak height equiva-
lent amount (3lg) of a commercial HbA2 sample.
All samples shown were analyzed after storage of
blood lysates at 4C for >2 months. Although the
present method is also suitable for the detection of
the therapeutically relevant HBBT87Q variant45,52
and would thus allow post-treatment analyses
of corresponding gene addition experiments in
the presence of normal HBB (see Supplementary
Fig. S6), separation and precise quantification of
normal and T87Q b-globin chains would benefit
from variant-specific optimization of conditions. Of
note, the molar absorption of proteins is dependent
on solvent conditions, such as pH,53 so that changes
in the solvent affect relative absorption of globin
chains (as illustrated by differences in relative c-
globin peak areas for same-sample separation of
cord blood by two different protocols on the same
C18 Jupiter column; Supplementary Fig. S5). Con-
sequently, total absorption of b- and a-like globin
chains is not necessarily identical for normal sam-
ples. Whereas absolute quantification will require
absolute external standards, relative quantification
is instead performedbynormalization to an internal
reference peak assumed constant (such as a-globin
for b-hemoglobinopathies) followed by calculation of
fold-changes compared to a control sample. In this
vein and of value for the analyses of rare samples,
the present protocol is able to detect b- to a-globin
ratios for sample amounts as low as 0.75 nL of PB
(equivalent to 113ng of hemoglobin; see Supple-
mentary Fig. S7). In the following, typical gene and
cell therapy applications were chose to demonstrate
the utility of the analysis, including application-
specific optimization of the method for co-detection
of human and murine b-globin chains.
Analyzing differentiation of HUDEP-2 cells
HUDEP-2 cells have been adopted by many
groups as a cell linewith properties similar tohuman
adult CD34+ basophilic erythroblasts, with ongoing
optimization of differentiation protocols.20,43 These
cells proliferate and survive owing to doxycycline-
inducible transgene expression of human papilloma
virus 16proteinsE6/E7,whosedownregulationupon
doxycycline withdrawal in turn allows erythroid
differentiation. Here, RP-HPLC was employed to
assess globin chain expression after 4 days of dif-
ferentiation at a doxycycline concentration of 2.5lg/
mL (Fig. 2a), and the state of differentiation was
analyzed with corresponding cytocentrifugation
analysis (Fig. 2b), which has lower sample require-
ments than alternative flow-cytometry analysis of
erythroid differentiation.20,54
Assessment of c-globin induction after
genome editing of CD34+ cells
With the advent of the versatile CRISPR/Cas9
genome-editing platform,55 gene disruption by the
efficient NHEJ pathway has been adopted bymany
groups for functional analyses and even for cor-
rection of disease.56–60 Disruption of the open
reading frame, however, has a fixed percentage of
in-frame repair, which might maintain partial
function of the target gene. This observation was
clearly established for the repetitive, structural
dystrophin protein,61 but might to some extent also
hold for NHEJ-mediated disruption of the tran-
scription factor and c-globin repressor BCL11A,62
where it would thus lower the efficiency of c-globin
induction. This prompted a comparison of the dis-
ruption of BCL11A exon 1 with disruption of its
start codon, where most types of insertion or dele-
tion would abolish any production of functional
BCL11A protein. Thus, primary CD34+ cells of a
carrier for the HBBIVSI-110(G>A) mutation were
treated with buffer only, Cas9 only, and dual-
promoter CRISRP/Cas9 lentiviral vectors, disrupt-
ing either the BCL11A start codon or a 5¢-proximal
target of its exon 1, respectively. We chose a carrier
sample for this analysis, arguing that cellular sat-
uration of b-like globin expression would be reduced
compared to a normal sample and that the level of
c-globin background expression would be lower
than in a thalassemic sample.63 Independent ana-
lyses for the two designer nucleases in question
using TIDE-based decomposition of sequence traces
indicated for an independent sample that 70% and
52% of editing events for the start-codon-specific
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Figure 3. Assessment of globin chain expression in primary human HSPCs after clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9-mediated BCL11A knockout. (a) T7 endonuclease I (T7EI) assay performed 48 h after transduction for primary cells from a b-thalassemia
carrier treated with buffer only (untransduced), Cas9-only vector (Cas9-only), CRISPR/Cas9 targeting the BCL11A start codon (start codon), and the BCL11A exon 1
(exon 1), as indicated. Cells were incubated for an additional 96 h without puromycin enrichment of nuclease-bearing cells before protein-based analyses. (b) Same-
sample immunoblot analysis for detection of c-globin, a-globin, and same-gel, same-membrane b-actin loading control. For clarity, lanes shown for immunoblots have
been excised digitally from larger membrane images comprising additional samples. Quantifications are based on the volume plots shown and a-globin normalization
for differentiation, with same-membrane, same-lane b-actin (as indicated by a black bar lining same-membrane samples) normalization for loading of each globin blot.
(c) Same-sample HPLC analysis using the standard protocol given in Table 1. Colored insets show contour plots for the PDA detector from 190 to 400 nm (on the
vertical axis; tick marks indicate 200 nm and 50-nm increments from top to bottom) and from 0 to 8min (on the horizontal axis; tick marks indicate 0min and 2-min
increments from left to right). (d) Bar chart showing an alignment of immunoblot (IB) data and RP-HPLC data for changes in the ratio of c-globin to a-globin (c/a)
relative to Cas9-only control, additionally displaying also the differential effect on Gc and Ac and the therapeutically most relevant ratio of b-like globins (combining b-,
d-, and c-globin peaks) to a-globin for the RP-HPLC analysis. For clarity, only data without normalization for disruption efficiencies are shown. b, b-globin; Gc, Gc-
globin, Ac, Ac-globin; a, a-globin; h, heme; act, b-actin. Measurements and ratios for this figure are summarized in Supplementary Table S2.
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nuclease and the exon-1-targeting nuclease, re-
spectively, introduced a single-nucleotide inser-
tion (Supplementary Fig. S8). For the present
sample, start-codon disruption had an overall ef-
ficiency of 9.7%, that of exon 1 of 14.6%, as de-
tected by T7E1 assay (Fig. 3a) 24 h after onset of
erythroid differentiation. These indicative differ-
ences in disruption efficiencies, albeit an under-
estimation of disruption achieved at the culture
end point, could be used to normalize detected
changes in c-globin expression and thus allow
functional comparison independent of differential
transduction efficiencies, as shown in parentheses
below. Immunoblots (Fig. 3b) and same-sample
RP-HPLC analysis (Fig. 3c) revealed consistent
results of an induction of c-globin expression with
both dual-promoter vectors, with slight deviation
in the relative c-globin induction by start-codon
and exon-1 disruption. Measured by RP-HPLC,
raw (and efficiency-normalized) fold changes of
c-globin were 3.0 · (22.2 · ) for start codon and
3.4 · (17.5 · ) for exon-1 targeting compared to
Cas9-only. Critically, RP-HPLC analysis avoided
normalization of same-sample analyses, which is
required across membranes for immunoblotting,
and in contrast to immunoblots showed greater
c-globin induction by exon-1 targeting compared
to start-codon targeting before normalization
for disruption efficiencies (Fig. 3d). Additionally,
the RP-HPLC analysis allowed differential quan-
tification of induction for each c-globin chain,
showing for this sample preferential induction of
Gc for both BCL11A-specific designer nucleases
(with Gc:Ac = 0.8 for SC and Gc:Ac = 0.9 for Exon 1 in
bulk cultures) compared to the Cas9 control
(Gc:Ac = 0.3), toward a restoration of a fetal c-globin
expression pattern of predominantly Gc.64,65Whereas
for immunoblots sample material for additional
analysis of b-globin expression was insufficient,
a single analysis run by RP-HPLC allowed the
therapeutically most relevant quantification of
the overall balance of b-globin- to a-globin-like
chains. Analyses comprising allmajor globin chains
are critical for the assessment of treatment effi-
ciency in b-thalassemia patients and in the present
case of a b-thalassemia carrier revealed a concom-
itant decrease of b-globin expression and no overall
increase of b-like globin chains after induction of
c-globin. This was in agreement with observations
for normal individuals66 and with the expectation
that erythrocytes from healthy carriers already
produce saturating amounts of b-like globin chains.
Detection of human b-globin in humanized
mouse models
Preclinical assessment of HBB gene addition in
animal models, be it in murine HSCs of thalasse-
mic animals or in human HSCs transplanted into
immunodeficient mice, usually necessitates the
detection of human b-globin chains against a mu-
rine globin background. To this end, this study set
out to develop a modified protocol for the separa-
tion of murine and human b-globin chains. At
standard operating temperatures from room tem-
perature to 70C, use of different organic solvents,
such as isopropanol, methanol and 3:1 (v:v) aceto-
nitrile:methanol, against 0.1% TFA did not achieve
separation of b-globin chains from both species
(data not shown). Variation of temperature for an
otherwise identical HPLC gradient (Supplemen-
tary Fig. S2) showed that extremes of temperature
for standard HPLC equipment (0–4C or 85C) al-
lowed separation of murine and human b-globin
chains for the original setup of column and solvent
combination. Frequent operation at acidic pH and
at high temperatures would be detrimental to col-
umn life, which prompted separation at 4C. After
trying different combinations of baseline and gra-
dient concentrations, the study arrived at the spe-
cific combination of baseline and gradient running
phase composition given in Table 2 and illustrated
for representative samples in Fig. 4. This is a
compromise between alternative conditions that
either achieved complete baseline separation of
human and murine b-globin chains for broad and
shallow peaks, or that showed overlap between
both chains at albeit narrower and thus more ac-
curately quantifiable peaks (see Supplementary
Fig. S3). The specific hybrid protocol does not re-
solve Hbbs from Hbbd mouse strains, but detects
additional globin peaks for CD-1 and DBA mouse
strains (see Supplementary Fig. S1). Most impor-
tantly, the protocol allows separation and quanti-
fication of murine and human a- and b-globin
Figure 4. Detection of murine and human b-globin chains. Chromatogram of sample readout at 190 nm (1 nm bandwidth) for injection of 12 nL
peripheral blood in a volume of 3lL, background-subtracted for a 3lL water-only sample. Analyses are shown for murine peripheral blood (Mm), human
peripheral blood (Hs), a mixture of murine and human peripheral blood at a volume ratio 3:1 (Mm:Hs 3:1), and peripheral blood of a transgenic mouse harboring
the human b-globin locus. Injection is visible as a peak at 3.1min. Other relevant peaks are identified underneath each chromatogram as murine a-globin (Ma),
murine b-globin (Mb), human b-globin (Hb), and human a-globin (Ha). Colored insets show contour plots for the PDA detector from 190 to 400 nm (on the
vertical axis; tick marks indicate 200 nm and 50-nm increments from top to bottom) and from 0 to 8min (on the horizontal axis; tick marks indicate 0min and
2-min increments from left to right). Heme elutes between injections at approximately 9min (not shown).
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chains, for example for mixtures of murine and
human peripheral blood (Fig. 4c) and for mice
transgenic for the human b-globin locus (Fig. 4d),
and would thus be suitable for the analysis of hu-
man–mouse chimeric blood, for routine screening
of HBB-transgenic animals (see Supplementary
Data for automatic analysis of 45mouse samples in
6.5 h), and for follow-up of lentiviral HBB gene-
addition in thalassemic mice.
DISCUSSION
This article presents two optimized RP-HPLC
analysis protocols for rapid quantification of human
globin chains and combined quantification of murine
and human globin chains, respectively, and explores
their fields of application in gene therapy studies. To
showcase the method, this study demonstrated the
suitability of core-shell-based RP-HPLC columns for
rapid and highly sensitive routine blood globin-chain
measurements, assessment of in vitro erythroid
differentiation, quantification of c-globin induction
after genome disruption by designer nucleases, de-
tection of HBBT87Q lentiviral transgene expression
in normal human background, and detection of hu-
man globin chains against murine background in
chimeric or transgenic blood samples. Moreover,
high-quality readouts from crude blood lysates after
prolonged storage at 4C or based on frozen cell pel-
lets validated the established methodology as a ro-
bust tool for analyses of third-party samples in
collaborations. In order to demonstrate the utility of
themethods described, they were used to investigate
different phenomena for the gene therapy of hemo-
globinopathies. First, analysis of BCL11A knockout
allowed differential quantification of induction for
Gc- and Ac-globin chains. Second, comparison of the
start codon and of a proximal exon-1 region of
BCL11A for NHEJ-mediated disruption showed
comparable efficiency for both approaches, in line
with the finding that themajority of exon-1 targeting
events introduced a +1 frameshift. Third, the con-
straints on protein expression and competition at the
b-globin locus were demonstrated for in vitro differ-
entiation of gene-edited primary human HSCs of a
b-thalassemia carrier, by showing that, as for carri-
ers in vivo, induction of c-globin expression does
not alter the overall balance of a-globin- to b-globin-
like chains but instead leads to concomitant down-
regulation of b-globin. For additional applications,
including baseline separation and accurate quan-
tification of HBBT87Q, for the detection of other ther-
apeutically relevant b-globin variants, such as bE and
bC and the highly anti-sickling HBBG16D,E22A,T87Q
variant,67whichwerenot available to this study, the
current protocols may serve as a template for the
establishment of dedicated rapid analysismethods.
In conclusion, the RP-HPLC protocols presented
here allow single-step assessment of globin ex-
pression for precise, simple and inexpensive
quantification of human globin chains in human
and murine samples. Ease of sample preparation,
automation and speed of analyses, and minimal
sample requirements make the present core-shell-
based RP-HPLC particularly suitable for precious
primary and gene therapy–related cell material.
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